A Phase 1 interventional study of Lasmiditan and Sumatriptan in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-27.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess whether taking lasmiditan and sumatriptan together will have any additional effects on heart rate and blood pressure compared to taking lasmiditan and sumatriptan individually. This study will also look at the amount of study drug that gets into the blood stream and how long it takes the body to get rid of it when these two drugs are taken together.
This study will last about 21 days, not including the screening. Participants will spend 16 days/15 nights in the clinical research unit (CRU) followed by follow-up. Screening is required within 28 days prior to the start of the study.
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral dose of 200 milligram (mg) lasmiditan tablet and single oral dose of 100 mg sumatriptan tablet in one of four treatment periods.
Drug: Lasmiditan · Drug: Sumatriptan
Single oral dose of 200 mg lasmiditan tablet and single oral dose of placebo tablet in one of four treatment periods.
Drug: Lasmiditan · Drug: Placebo for Sumatriptan
Single oral dose of 100 mg sumatriptan tablet and single oral dose of placebo tablet in one of four treatment periods.
Drug: Sumatriptan · Drug: Placebo for Lasmiditan
Oral doses of placebo tablets in one of four treatment periods.
Drug: Placebo for Lasmiditan · Drug: Placebo for Sumatriptan
Administered orally
Also known as: LY573144
Administered orally
Administered orally
Administered orally
Pharmacodynamics (PD): Change From Baseline in Mean 24-hour Systolic Blood Pressure (SBP)
Systolic Blood Pressure (SBP) was measured by using a 24-hour Ambulatory Blood Pressure Monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least squares (LS) mean peak changes from baseline were calculated using a linear mixed-effects model with baseline, treatment, period, and sequence as fixed effects and participant as a random effect.
Time frame: Baseline (Day 1), Day 2
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lasmiditan and Sumatriptan
PK: Cmax of Lasmiditan and Sumatriptan was evaluated.
Time frame: Lasmiditan: Predose, 0.5, 1, 1.5,2, 2.5, 3, 4, 6, 8, 12 , 24 ,36 and 48 hours(h) postdose; Sumatriptan: Predose, 0.5, 1, 1.5,2, 2.5, 3, 4, 6, 8, 12 and 24 h postdose
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0 ∞]) of Lasmiditan and Sumatriptan
PK: AUC(0 ∞) of Lasmiditan and Sumatriptan was evaluated.
Time frame: Lasmiditan: Predose, 0.5, 1, 1.5,2, 2.5, 3, 4, 6, 8, 12, 24 ,36 and 48 h postdose; Sumatriptan: Predose, 0.5, 1, 1.5,2, 2.5, 3, 4, 6, 8, 12 and 24 h postdose
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 10 | 10 | 10 | 10 |
| Received at least 1 dose of study drug | 10 | 10 | 10 | 10 |
| Completed | 10 | 10 | 10 | 9 |
| Not completed | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 10 | 10 | 10 | 9 |
| Completed | 10 | 10 | 10 | 9 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 10 | 10 | 10 | 9 |
| Completed | 10 | 10 | 10 | 9 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 10 | 10 | 10 | 9 |
| Completed | 10 | 10 | 10 | 9 |
| Not completed | 0 | 0 | 0 | 0 |
Systolic Blood Pressure (SBP) was measured by using a 24-hour Ambulatory Blood Pressure Monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least squares (LS) mean peak changes from baseline were calculated using a linear mixed-effects model with baseline, treatment, period, and sequence as fixed effects and participant as a random effect.
| Millimeters of mercury (mmHg) | 200 mg Lasmiditan + 100 mg Sumatriptan (A): | 200 mg Lasmiditan + Placebo (B) | 100 mg Sumatriptan + Placebo (C) | Placebo + Placebo (D) |
|---|---|---|---|---|
| Pharmacodynamics (PD): Change From Baseline in Mean 24-hour Systolic Blood Pressure (SBP) | 13.81 (11.83 to 15.79) | 12.17 (10.47 to 13.87) | 13.63 (11.65 to 15.61) | 11.42 (9.74 to 13.09) |
PK: Cmax of Lasmiditan and Sumatriptan was evaluated.
| nanogram per milliliter (ng/mL) | 200 mg Lasmiditan + 100 mg Sumatriptan (A):Analyte: Lasmiditan | 200 mg Lasmiditan + Placebo (B): Analyte: Lasmiditan | 200 mg Lasmiditan +100 mg Sumatriptan (A):Analyte: Sumatriptan | 100 mg Sumatriptan + Placebo (C): Analyte: Sumatriptan |
|---|---|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lasmiditan and Sumatriptan | 304 ± 39 | 328 ± 32 | 56.8 ± 36 | 50.7 ± 42 |
PK: AUC(0 ∞) of Lasmiditan and Sumatriptan was evaluated.
| nanogram*hour per milliliter (ng*hr/mL) | 200mg Lasmiditan + 100mg Sumatriptan (A): Analyte: Lasmiditan | 200 mg Lasmiditan + Placebo (B): Analyte: Lasmiditan | 200 mg Lasmiditan +100 mg Sumatriptan (A):Analyte: Sumatriptan | 100 mg Sumatriptan + Placebo (C): Analyte: Sumatriptan |
|---|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0 ∞]) of Lasmiditan and Sumatriptan | 2110 ± 37 | 2170 ± 33 | 253 ± 28 | 240 ± 29 |
Collected over Up To 36 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 200 mg Lasmiditan + 100 mg Sumatriptan (A) | 0/39 (0%) | 0/39 (0%) | 4/39 (10.3%) |
| 200 mg Lasmiditan + Placebo (B) | 0/39 (0%) | 0/39 (0%) | 7/39 (17.9%) |
| 100 mg Sumatriptan + Placebo (C) | 0/39 (0%) | 0/39 (0%) | 3/39 (7.7%) |
| Placebo + Placebo (D) | 0/40 (0%) | 0/40 (0%) | 1/40 (2.5%) |
| Event | 200 mg Lasmiditan + 100 mg Sumatriptan (A) | 200 mg Lasmiditan + Placebo (B) | 100 mg Sumatriptan + Placebo (C) | Placebo + Placebo (D) |
|---|---|---|---|---|
| DizzinessNervous system disorders | 3/39 | 5/39 | 1/39 | 0/40 |
| Upper respiratory tract infectionInfections and infestations | 0/39 | 2/39 | 1/39 | 0/40 |
| HeadacheNervous system disorders | 2/39 | 0/39 | 2/39 | 1/40 |
All enrolled participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Overall |
|---|---|
| Mean | 40.1 ± 12.5 |
| Sex: Female, Male(Participants) | Overall |
|---|---|
| Female | 15 |
| Male | 25 |
| Ethnicity (NIH/OMB)(Participants) | Overall |
|---|---|
| Hispanic or Latino | 19 |
| Not Hispanic or Latino | 21 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Overall |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 16 |
| White | 23 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(Participants) | Overall |
|---|---|
| United States | 40 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2017 to primary completion in Dec 2017, 2 months.
Results were first posted in Nov 2019, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lasmiditan · Sumatriptan